Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Analyst
Matt Sykes
Period: Reporting periods mapped to calendar 2024 Q4 – 2025 Q1 (2 quarters).
- Questions
- 20on tracked calls
- Challenge rate
- 5%1 of 20 questions
- Companies
- 7questioned at least once
- Reporting periods
- 2with questions
These figures cover the whole profile: every tracked question, all reporting periods.
How to read these numbers
Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.
Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.
No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.
Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.
Small samples. Profiles with fewer than 10 questions are marked Limited sample.
Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.
Questions asked
Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.
Showing 20 of 20 questions from 7 companies
MTDMettler Toledo4 questions · 2 reporting periods · 0 of 4 challenging
Calendar 2025 Q1
Patrick, one for you just on services growth. You said 6% in the quarter. A little bit below kind of the run rate you were doing last year
Show response
Patrick confirmed mid-to-high single-digit service growth forecast for full year. Shawn noted FX now neutral for year (was 2% headwind previously).
Do you think that if this tariff situation lasts a little bit longer than expected, meaning beyond Q2, there could be some shifts in the competitive landscape in China
Show response
Patrick emphasized local manufacturing, local R&D, perceived as Chinese company by customers. Few US imports to China. Strong competitive position regardless of tariff duration.
Calendar 2024 Q4
you do have a manufacturing footprint there. Could you maybe remind us what your exposure is in terms of revenue shipped out of Mexico
Show response
Shawn quantified Mexico/Canada at ~2% of sales each with limited US exports, confident in pricing and supply chain mitigation options.
can we extrapolate sort of that improving demand among that customer segment in Europe into other developed market regions like the US
Show response
Patrick expressed confidence that European portfolio wins will translate to US over time as innovation triggers replacement cycles.
RVTYRevvity4 questions · 2 reporting periods · 1 of 4 challenging
Calendar 2025 Q1
wondering if the US had any kind of tariff pull forward just given the acceleration of high-single-digits
Show response
Max denied any pull-forward effect. Prahlad added Diagnostics products go from Europe to China, not from US.
Could you maybe kind of give us a refresh on the competitive landscape, how you're winning business?
Show response
Prahlad highlighted competitive positioning from Life Sciences integration but didn't specifically address margin impact of Signals scaling.
Calendar 2024 Q4
what are you looking for in terms of leading indicators in terms of seeing that turn?
Show response
Prahlad acknowledged recovery path for instruments but didn't commit to specific leading indicators beyond current customer conversations.
was there any element of budget flush or any one-off impact in Q4 to drive that growth rate
Show response
Prahlad definitively denied any budget flush effect, emphasizing organic recovery path.
WATWaters Corporation4 questions · 2 reporting periods · 0 of 4 challenging
Calendar 2025 Q1
Just on services, it came in a little bit lighter than what we were expecting. Is this just a natural output of just having a very high instrument placement growth
Show response
CFO attributed softer services to two fewer working days and lower third-party parts purchases.
does this make you want to take advantage of the environment to perhaps invest a little bit more in upstream, either organically or inorganically
Show response
Management firmly committed to downstream focus, citing light scattering-Empower integration and Alliance iS success as proof.
Calendar 2024 Q4
Can you talk through the benefits of your Empower software? And then, any particular application areas where you see higher attachment rates
Show response
CFO highlighted unique recurring revenue resilience at 6-7% through the downturn driven by Empower, service attachment and e-commerce.
can you talk through the strength you saw in the Academic and Government section this quarter? And then what your expectations are going into 2025
Show response
CFO noted Q4 A&G benefited from typical budget flush; less than 1% direct NIH exposure; low single-digit A&G growth assumed for 2025.
AAgilent Technologies2 questions · 1 reporting period · 0 of 2 challenging
Calendar 2024 Q4
Should we start to see a faster cycle of new product introductions due to the resegmentation, or is it gonna be similar to the pace that we've seen in the past
Show response
Padraig confirmed R&D acceleration from the restructuring with focus on key growth factors. Clear commitment to faster innovation.
Could you just provide a little bit more color on what's driving that growth? And how sustainable do you think that growth is, particularly in genomics as we move through 2025?
Show response
Simon May provided detailed breakdown of pathology and genomics drivers, including Magnus NGS library prep traction. Direct and thorough.
CRLCharles River Laboratories2 questions · 1 reporting period · 0 of 2 challenging
Calendar 2024 Q4
are you expecting any sort of improvement to that dynamic in the second half of 2025, or should we be thinking more about 2026
Show response
James was candid that pharma would be flat through 2025 with no recovery assumed, while biotech would be stable to slightly improving. No indication of when recovery materializes.
Could you just talk about academic as a whole, including NIH, what that is in terms of percentage of RMS?
Show response
James quantified academic/government at 40% of RMS and ~10% company-wide, with direct NIH exposure under 2%. Said relatively small revenue percentage means they should be fine.
IQVIQVIA2 questions · 1 reporting period · 0 of 2 challenging
Calendar 2025 Q1
opportunities for any potential margin expansion and kind of what you could do on the cost side
Show response
Bruehlman said implied margin change is almost entirely FX impact. Underlying margin picture unchanged with ongoing cost reduction and AI initiatives as margin tailwinds.
do you think that vendor consolidation trend, which has already been in place, will accelerate in this environment
Show response
Bousbib noted RFP flow still strong with stable win rates. Renewed all 22 strategic partnerships in 2024 and seeing benefits of expanded relationships in new RFPs.
Show 1 more company
TMOThermo Fisher Scientific2 questions · 1 reporting period · 0 of 2 challenging
Calendar 2025 Q1
could you maybe talk about any changes in order behavior or patterns where there's been a pull forward of inventories just to get ahead of tariffs
Show response
Casper said no pull-forward was observed given the short timeline between tariff announcement and implementation.
is it easier to flex an instrument manufacturing facility versus, say, consumables and reagents
Show response
Casper emphasized TMO's scale advantage with twin factories in multiple geographies but did not provide product-specific detail on flexibility timelines.
Challenge rate by company
Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.
| Company | Questions | Challenge rate |
|---|---|---|
| MTD Mettler Toledo | 4 | 0%none of 4 questions |
| RVTY Revvity | 4 | 25%1 of 4 questions |
| WAT Waters Corporation | 4 | 0%none of 4 questions |
| A Agilent Technologies | 2 | —Rate withheld: fewer than 3 questions |
| CRL Charles River Laboratories | 2 | —Rate withheld: fewer than 3 questions |
| IQV IQVIA | 2 | —Rate withheld: fewer than 3 questions |
| TMO Thermo Fisher Scientific | 2 | —Rate withheld: fewer than 3 questions |
- MTDMettler Toledo · 4 questions0%none of 4 questions
- RVTYRevvity · 4 questions25%1 of 4 questions
- WATWaters Corporation · 4 questions0%none of 4 questions
- AAgilent Technologies · 2 questions—rate withheld: under 3 questions
- CRLCharles River Laboratories · 2 questions—rate withheld: under 3 questions
- IQVIQVIA · 2 questions—rate withheld: under 3 questions
- TMOThermo Fisher Scientific · 2 questions—rate withheld: under 3 questions
Activity by reporting period
Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.
| Calendar period | Questions | Challenge rate | Companies |
|---|---|---|---|
| 2024 Q4 | 10 | 10%1 of 10 questions | 5 |
| 2025 Q1 | 10 | 0%none of 10 questions | 5 |
- 2024 Q410 questions · challenge rate 10% (1 of 10 questions) · 5 companies
- 2025 Q110 questions · challenge rate 0% (none of 10 questions) · 5 companies
Topics
Topics tagged on this analyst’s questions.
- Demand9
- Competitive Dynamics6
- Revenue Growth6
- Trade Tariffs4
- Supply Chain3
- Margin2
- Fx2
- Innovation & R&D2
- Macroeconomic2
- Cloud & AI1
Show all 14 topics
- M&A1
- Regulation Policy1
- Geographic Expansion1
- Capex Investment1